Form 6-K BioLineRx Ltd. For: Aug 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver
August 20, 2015 12:40 PM EDTRoth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier Thursday.
BLRX posted Q2 EPS of ($0.12), which was $0.04 worse than the analyst estimate of ($0.08).
Analyst Joseph Pantginis offered the following commentary, We currently view BL-8040 as the main value driver for the company with multiple near-term milestones expected. The most significant... More
BioLineRx (BLRX) Misses Q2 EPS by 4c
August 20, 2015 7:05 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More